MBP 3.23% 3.0¢ metabolic pharmaceuticals limited

mbp's new competitor ???????, page-11

  1. 762 Posts.
    Extract from the MBP announcement of 3 March 2003


    There were no clinically significant safety or tolerability concerns.

    The principle of AOD9604, already proven in animal studies, is to
    mimic the natural fat reducing properties of human growth hormone
    without producing any effects on blood sugar control or growth. As
    with previous studies there was no evidence of effects on either
    blood sugar control or on markers of growth.

    The numbers of adverse events in the treated groups were similar to
    the placebo group, except at the highest (60 mg) dose. At this dose,
    which is in excess of the anticipated effective dose for weight
    reduction (see below), there were a few occasions of abdominal
    discomfort of various kinds, mostly shortly after dose.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.